OmanDocSign in

Curriculum · Hematology

Unfractionated heparin versus low molecular weight heparin

What it is

Unfractionated heparin (UFH), low molecular weight heparin (LMWH) and fondaparinux are indirect parenteral anticoagulants that all work through antithrombin.

UFH activates anti-thrombin III, which forms a complex inhibiting clotting factors IIa and Xa as well as IX, XI and XII. LMWH - enoxaparin, tinzaparin - activates anti-thrombin III as well, and the two sources differ over what its complex inhibits: one writes the LMWH mechanism as a complex inhibiting clotting factor Xa, while the pharmacokinetic table sets Factor Inhibition for enoxaparin (LMWH) at IIa and Xa, beside IIa, Xa, IXa, XIa and XIIa for UFH. Fondaparinux is a synthetic derivative of LMWH and inhibits Xa only.

The molecular weight in kDa (mean) is 15,000 for UFH, 4000-5000 for enoxaparin and 1728 for fondaparinux. The anti-Xa:anti-IIa ratio is 1:1 for UFH and 2:1 to 4:1 for LMWH.

How it is treated

UFH is given intravenously and LMWH subcutaneously. Bioavailability after subcutaneous administration is 30% for UFH, 90% for enoxaparin and 100% for fondaparinux.

Half-life is short for UFH, about 1 hour (0.5-1.5, varies with dose), longer for LMWH at 3-6 hours (varies with CrCL) and 17-21 hours for fondaparinux. UFH is cleared rapidly by a saturable nonrenal route with first-order renal kinetics; LMWH and fondaparinux have renal clearance.

What can go wrong

Both share the same side effects: bleeding, osteoporosis, thrombocytopenia (HIT) and hyperkalemia due to hypoaldosteronism. HIT incidence is 1%-5% with UFH and 0.1%-1% with LMWH, with only case reports for fondaparinux; in case of HIT, fondaparinux is given.

Type 1 HIT is about 10-20%, within the first 5 days after beginning treatment, with moderate thrombocytopenia (>100,000 platelets/uL). It comes from direct interaction between heparin and platelets, with no antibodies involved, is clinically insignificant, and management is to continue heparin, since platelets usually return to normal with continued heparin administration, and monitor platelets.

Type 2 HIT is 1-5% for UFH and 0.1-1% for LMWH, on day 5-14, with a massive reduction to <100,000 platelets/uL or a decrease of >50% compared to baseline. Autoantibodies form against a complex of platelet factor 4 (PF4) and heparin and induce both thrombocytopenia and thrombosis. Bleeding is rare because the platelet nadir, the lowest point, is usually >20,000 platelets/uL; the risk that matters is thrombosis, venous more than arterial, involving the legs (for example DVT), cardiac vessels (for example myocardial infarction) and skin, with organ ischemia or infarction, skin necrosis and limb gangrene.

Management of type 2 HIT: treat presumptively as soon as it is suspected, discontinue all heparin-containing products immediately, send the confirmatory test, start non-heparin anticoagulation (often a direct thrombin inhibitor such as argatroban, not warfarin) until the platelet count has normalized (>150,000 platelets/uL), then transition to warfarin or another long-term oral anticoagulant for at least two months, and inform the patient of their heparin allergy.